UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 2230, 2018

ANTHERA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-34637		20-1852016
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

25801 Industrial Boulevard, Suite B, Hayward, California		94545
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (510) 856-5600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3 8.01. ~~Notice~~ ofOther ~~Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing~~Events.

On May 2230, 2018, Anthera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), ~~received~~announced athat ~~letter~~it ~~from~~will ~~The~~hold ~~Nasdaq Stock Market (“Nasdaq”) informing~~ the Company’s ~~that~~2018 ~~its~~annual ~~most~~meeting ~~recent~~on ~~Form~~December ~~10-Q for the period ended March 31~~3, 2018 ~~disclosed that~~ (the ~~Company~~“2018 ~~has~~Annual ~~suspended further clinical development of Sollpura and began to wind down activities including suspending further development of its only other licensed drug compound, blisibimod~~Meeting”). ~~The~~Further ~~Company~~information isregarding ~~exploring strategic transactions and noted that if a strategic transaction is not consummated,~~ the ~~Company~~2018 ~~may~~Annual beMeeting ~~required~~will ~~to dissolved or liquidate. In that regard, any strategic transaction that involves a merger or acquisition would likely~~ be amade ~~business~~available ~~combination~~to ~~that~~stockholders ~~results~~ in ~~“Change~~a ofdefinitive ~~Control”~~proxy ~~pursuant to Listing Rule 5110(a)~~statement, which ~~would~~will ~~require~~be ~~the~~filed post-transaction entity to satisfy all of Nasdaq’s initial listing criteria and to complete Nasdaq’s initial listing process. Furthermore, the bid price of the Company’s listed common stock was not in compliance with the ~~continued~~Securities ~~listing requirements due to the bid price closing at less than $1.00 for more than 30 consecutive business days,~~ and asExchange aCommission ~~result, does not comply with Listing Rule 5550~~(athe “SEC”)~~(2)~~.

~~The~~Stockholders ~~letter~~who ~~stated~~meet ~~that~~the requirements of the ~~Company~~proxy ~~may~~rules ~~appeal~~under the ~~Staff’s~~Securities ~~determination~~Exchange toAct aof ~~Hearings~~1934, ~~Panel~~as amended (the “~~Panel~~Exchange Act”), ~~within~~may ~~seven~~submit ~~days~~proposals ~~from~~to the ~~receipt~~Company’s Board of Directors (the ~~letter~~“Board”) to be presented at the 2018 Annual Meeting. A ~~hearing~~Such ~~request~~proposals ~~will~~must ~~stay~~comply with the ~~suspension~~requirements of Rule 14a-8 under the ~~Company’s~~Exchange ~~securities~~Act ~~pending~~and be submitted in writing by notice delivered or mailed by first-class United States mail, postage prepaid, to our Secretary at our principal executive offices at the ~~Panel’s~~address ~~decision. The~~set ~~Company~~forth ~~intends~~above ~~appeal~~no later than October 4, 2018 in order to be considered for inclusion in the ~~Staff’s~~proxy ~~determination~~materials to be disseminated by the Board for the 2018 Annual Meeting.

Stockholders who desire to bring business before the 2018 Annual Meeting, other than through a shareholder proposal pursuant to the SEC’s rules, must notify the Company’s Secretary in writing and provide the information required by the provision of the Company’s Amended and Restated Bylaws dealing with shareholder proposals. Notice must be received at the Company’s principal executive offices no later than October 4, 2018. The requirements for such notice are set forth in the Company’s Amended and Restated Bylaws. The Company reserves the right to reject, rule out of order, or take other appropriate action with respect to any proposal that does not comply with these and other applicable requirements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 23, 2018	Anthera Pharmaceuticals, Inc.
Date: May 30, 2018	Anthera Pharmaceuticals, Inc.
	By:	/s/ J. Craig Thompson
		J. Craig Thompson
		President and CEO

Filing Compare · Anthera Pharmaceuticals Inc